Oncotrail RGCC: Monitor Cancer Progression for Specific Cancers

Observe cancer progression & treatment response

The Oncotrail RGCC test is a specialized monitoring test that builds on the foundation of the Oncotrace test. It is specifically designed to track Circulating Tumor Cells (CTCs) associated with particular cancer types:  

• Breast cancer 
• Colon cancer 
• Gastrointestinal (GI) cancer 
• Lung cancer 
• Melanoma 
• Prostate cancer 
• Sarcoma 

By identifying and analyzing cancer-specific markers in the bloodstream, the Oncotrail RGCC test provides physicians with valuable insights into disease progression and treatment effectiveness. It enables clinicians to monitor tumor behavior, evaluate how patients are responding to therapy, and detect early signs of relapse or metastasis. 

The cancer blood test Oncotrail can be used both during active treatment, such as chemotherapy, and after remission, helping guide personalized and timely treatment decisions for better patient outcomes. 

How does the Oncotrail RGCC test work?

The Oncotrail RGCC test focuses on specific cancer types, breast, colon, GI, lung, melanoma, prostate, and sarcoma, and evaluates a unique set of biomarkers relevant to each. 

For example, the breast cancer Oncotrail RGCC test examines only markers associated with breast cancer, while the prostate cancer Oncotrail RGCC test targets markers specific to prostate tumors. This tailored approach ensures a precise and clinically relevant analysis, giving physicians a clear understanding of the cancer’s biological activity and guiding more informed therapeutic strategies. 

Through a simple blood draw, the test from RGCC establishes baseline values for CTC count, phenotype markers, and stemness markers in the bloodstream. Together, these parameters provide a detailed picture of cancer activity and treatment response. 

• Circulating Tumor Cell (CTC) count: Measures the number of cancer cells circulating in the bloodstream. Tracking changes in this count helps physicians assess treatment effectiveness, disease progression, and make timely, personalized clinical decisions. 

• Phenotype markers: The immunophenotype helps reveal important information about the characteristics of the cancer, such as the likelihood of metastasis, disease progression, and potential resistance to therapies. 

• Stemness markers: Indicate the activity and regenerative potential of cancer stem cells. The presence of active stemness markers suggests the need to continue treatment, even when CTC counts appear low, ensuring that residual disease is not overlooked.